Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
Retrieved on:
Thursday, December 1, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, AstraZeneca, Natural killer T cell, Adenosine, Euronext Paris, Immune system, Pharmacokinetics, Antibody, Sanofi, Cancer, Novo Nordisk, Clinic, CD39, Partnership, Patient, Tumor microenvironment, Oncology, UNIL, Trastuzumab, Department of Oncology, University of Cambridge, IPHA, ESMO, Lung cancer, Neoplasm, IPC, ATP, IPH, Bristol Myers Squibb, Congress, Durvalumab, Immunity, European Society for Medical Oncology, Safety, Vaccine, Pharmaceutical industry, MD, Intrinsic and extrinsic properties
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.
Key Points:
- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.
- IPH5201 is a CD39-blocking monoclonal antibody that may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment.
- By targeting the adenosine immunosuppressive pathway, IPH5301 has the potential to promote anti-tumor immune responses across a wide range of tumors.
- Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.